• Home
• About
• Log In
• Register
• Search
• Current
• Archives
• Announcements
• Waiver
• AAPM
• IOMP
• COMP/OCPM
• Advertising
• Annual meeting
• Home links
• Associated Organizations
• Submission Guidelines

Home > Vol 8, No 2 (2007) > sowards

Monte Carlo dosimetric

characterization of the

IsoAid ADVANTAGE ¹⁰³Pd

 

brachytherapy source

 

Keith T. Sowards
Department of Radiation Oncology, University of Louisville, James Brown Cancer Center, Louisville, Kentucky
ktsowa01@louisville.edu

Received 13 October 2006; accepted 5 January 2007

For roughly 25 years, ¹²⁵I and ¹⁰³Pd sources have been used in the treatment of various malignant diseases such as prostate cancer. Various new sources have been marketed and produced to meet the demand for new sources to use in treatment. Recently, IsoAID LLC created the ADVANTAGE ¹⁰³Pd source. Various dosimetric parameters must be determined to facilitate treatment planning using this source. Theoretical determination of dosimetric characteristics, dose rate constant, radial dose function, and anisotropy function for this new source followed the American Association of Physicists in Medicine (AAPM) Task Group 43U1 recommendations. Theoretical calculations were performed in liquid water using the PTRAN Monte Carlo code version 7.44. The radial dose function of the new source was calculated in liquid water at distances up to 10.0 cm, and the anisotropy function, at distances ranging from 0.5 cm to 7.0 cm. The anisotropy factors and anisotropy constant were derived from the anisotropy function. The results in water indicate that the dose rate constant is 0.709 ± 0.014 cGy·h^­1·U^­1 and that the anisotropy constant is 0.880 ± 0.040. The dosimetric characteristics of this new source compare favorably with those of other commercially available ¹⁰³Pd sources.

PACS: 87.53.Jw

Key words: ¹⁰³Pd, dosimetry, Monte Carlo, brachytherapy

Keith T. Sowards, University of Louisville, James Brown Cancer Center, Department of Radiation Oncology, 529 South Jackson Street, Louisville, KY 40202 U.S.A.; phone: 502-561­2700; fax: 502-561­2709; email: ktsowa01@louisville.edu

 

I. INTRODUCTION

For approximately 25 years, ¹⁰³Pd brachytherapy sources have been produced for use in interstitial implants in various tumor sites. Sources using ¹⁰³Pd are favored because their low-energy photon emissions provide a rapid decrease in dose with increasing distance, minimizing the dose to normal tissues.

Use of ultrasound-guided brachytherapy seed implantation for prostate cancer has increased greatly since the technique was developed in the early 1980s. The reasons for the increase are many, including patient convenience (one treatment versus many for external-beam radiotherapy), reduced side effects as compared with radical prostatectomy, and greater cost effectiveness.^(1­4) With a shortage of available seeds and an increase in the number of procedures being performed nationally, several manufacturers, including IsoAid (IsoAid LLC, Port Richey, FL), have developed new ¹⁰³Pd sources to meet the increasing demand.

II. MATERIALS AND METHODS

A. Source of ¹⁰³Pd

The ADVANTAGE ¹⁰³Pd source has a physical length of 4.5 mm and an outer diameter of 0.8 mm. To create the four active 0.5-mm polystyrene spheres, ¹⁰³Pd isotope is absorbed throughout the spheres, which are then encapsulated in a 0.05-mm­thick titanium capsule (Fig. 1). A silver rod, 0.5 mm in diameter and 1.25 mm in length, serves as an X-ray marker and is placed between the pair of spheres at each end of the capsule. An active length of 3.4 mm was assumed for this source during calculation of the source parameters.

B. Monte Carlo simulation

Dose distributions for the ADVANTAGE source were calculated in liquid water using the PTRAN Monte Carlo code.^(5­7) Simulations were performed for up to 10 million histories divided into one hundred batches. By combining this number of histories with use of a distance-and-attenuation-averaged, bounded, next-flight point-kerma estimator⁽⁵⁾ standard errors about the mean (67% confidence intervals) ranging from 1.5% (near the source: r < 3 cm) to 5%­6% (far from the source: r > 5 cm) were achieved.

One assumption made in the Monte Carlo simulation of the dose distributions around the source was that a uniform distribution of the ¹⁰³Pd isotope is present within each polystyrene sphere. A density of 1.046 g/cm³ was assumed for each polystyrene sphere. The X-ray marker at the center of the source is 1.25 mm in length and 0.5 mm in diameter. The overall physical length of the source is 4.5 mm, with an outer diameter of 0.8 mm. The internal cavity of the source is filled with dry air. The PTRAN code used the ¹⁰³Pd photon spectrum extracted from the Medical Internal Radiation Dosimetry (MIRD) pamphlet 10.⁽⁶⁾

The Monte Carlo­simulated dose rate constant was obtained by calculating the kerma rate to water at the reference point (1 cm, π/2) in a medium and then dividing that result by the simulated air kerma (S_K) strength of the source. The S_K was determined by calculating the air kerma rate at 10 cm distance and correcting for the inverse square of the distance to obtain the value at 1 cm while suppressing characteristic X-ray production. It is understood, but impractical, to simulate at the distance that the National Institute of Standards and Technology (NIST) uses (100 cm). Such a simulation would have required extremely long run times to yield even marginal uncertainty levels. Using 10 cm as a reference yields good uncertainty at a great enough distance to fairly approximate true NIST calibration standards. In the calculations, simulations in air were performed with the titanium characteristic X-ray production suppressed. The air kerma rate strength per unit contained activity is given in cGy·cm²·h^­1· mCi^­1.

Fig. 1. Schematic diagram of the ADVANTAGE 103Pd brachytherapy source (courtesy of IsoAid LLC). The area between the capsule and the X-ray marker is filled with air.

C. Dosimetry technique

Characteristics of the source were determined theoretically according to Task Group Report No. 43 (TG-43U1)^(8­10) from the American Association of Physicists in Medicine (AAPM). Under that protocol, the dose distribution around a sealed brachytherapy source can be determined using the formalism

(1)

where S_K is the air kerma strength of the source, Λ is the dose rate constant at a reference point (r₀, θ₀) or (1 cm, π/2), G(r,θ) is the geometry function, g(r) is the radial dose function, and F(r,θ) is the anisotropy function. The above quantities are thoroughly defined and discussed in great detail in TG-43(U1) and that discussion will therefore not be repeated here.

The goal of the present project was to compare the calculated dosimetric parameters of the IsoAid ADVANTAGE ¹⁰³Pd brachytherapy source with those of other commercially available ¹⁰³Pd sources. The determinations were performed according to the methodology outlined in TG-43U1^(8­10) and in accordance with the AAPM recommendations for source calibration.⁽¹¹⁾

III. RESULTS

The dose rate constant, Λ, of the ADVANTAGE ¹⁰³Pd source was determined using the equation

(2)

As shown in Table 1, the Monte Carlo calculations yielded a value of 0.709 ± 0.014 cGy·h^­1·U ^­1 in liquid water. The uncertainty of the Monte Carlo simulation was determined by combining the uncertainties of the dose rate calculated in medium and the calculated air kerma rate. The air kerma rate was obtained from the Monte Carlo data by simulating the dose rate at 1 cm in phantom and then dividing that result by the simulated dose rate at 10 cm in air with characteristic X-ray production suppressed. The resulting value was then corrected for the effects of the inverse square law.

Table 1. Comparison of the dose rate constant, L, of the ADVANTAGE 103Pd brachytherapy source with the dose rate constants of the Theragenics Model 200, Best Industries 103Pd, and NAS MED3633 sources

a 1U = 1 cGy·cm2·h­1 . b Corrected per the TG-43(U1) recommendations of the American Association of Physicists in Medicine.

The radial dose function of the source was calculated in water from 0.1 cm to 10 cm. The uncertainty of the calculated data is ±3%. Fig. 2 shows a comparison between the calculated g(r) of the ADVANTAGE source and a selection of other commercially available sources. Table 2 presents the values of g(r) in water. Those values were obtained by simulating the dose rate at each g(r) distance and then normalizing to the simulated dose rate at 1 cm. The result was then corrected for inverse square relation as per TG-43.

Fig. 2. Comparison in water of the Monte Carlo­calculated radial dose function of the ADVANTAGE 103Pd source with radial dose functions of other commercially available sources.

Table 2. The calculated radial dose function of the ADVANTAGE 103Pd brachytherapy source in liquid water

Many treatment planning systems require a polynomial fit to g(r). For use of this data in those various treatment planning systems, the calculated g(r) in water in the range of 0.1 cm to 10 cm was fitted to a fifth-order polynomial function defined as follows:

(3)

where a₀ = 1.1983, a₁ = 7.3502E^­2, a₂ = ­3.1789E^­1, a₃ = 9.1913E^­2, a₄ = ­9.9569E^­3, and a₅ = 3.7557E^­4. This fifth-order polynomial fit has been found to fail to accurately reproduce the g(r) at radial distances greater that 10 cm; however, it is accurate at distances less than 10 cm.

The anisotropy function of the source was calculated in liquid water for distances ranging from 0.5 cm to 7 cm. Those values were obtained by simulating the dose rate at each angle and normalizing to the dose rate at 90 degrees and at the radial distance in question. The result was then corrected using the geometry function relationship as defined in TG-43. The uncertainties of the calculated values range from ±5% to ±6%.

Fig. 3 shows the variation of F(r,θ) in water as a function of distance from the source. Figs. 4 and 5 compare the anisotropy function of the ADVANTAGE source with those of several other commercially available sources at 1 cm and 5 cm respectively. From the anisotropy function of the ADVANTAGE source, the anisotropy factors φ_an(r) and the anisotropy constant have been extracted. Table 3 shows the anisotropy functions, anisotropy factors, and anisotropy constant of the ADVANTAGE source in liquid water. Table 4 compares the anisotropy factors and constant with those of other commercially available sources. The calculated anisotropy constant for the ADVANTAGE source in water was 0.880 ± 0.040.

Fig. 3. Variation of the Monte Carlo­simulated F(r,q) of the ADVANTAGE 103Pd source in liquid water at distances ranging from 0.5 cm to 7 cm.

 

Fig. 4. Comparison in liquid water at 1 cm radius of the Monte Carlo­simulated anisotropy functions of the ADVANTAGE 103Pd source with the anisotropy functions of other commercially available sources.

 

Fig. 5. Comparison in liquid water at 5 cm radius of the Monte Carlo­simulated anisotropy function of the ADVANTAGE 103Pd source with the anisotropy functions of other commercially available sources.

 

Table 3. Monte Carlo­simulated two-dimensional anisotropy function of the ADVANTAGE 103Pd brachytherapy source in liquid water

 

Table 4. Comparison of the Monte Carlo­simulated anisotropy factors and constant of the ADVANTAGE 103Pd source and other commercially available sources in liquid water

IV. DISCUSSION AND CONCLUSIONS

The dose rate constant of the ADVANTAGE ¹⁰³Pd source was found to be 0.709 ± 0.014 cGy·h^­1·U ^­1. This value is in good agreement with other commercially available ¹⁰³Pd sources. Table 1 compares the dose rate constant of the ADVANTAGE source with the dose rate constants calculated for several other commercially available ¹⁰³Pd sources such as the Model 200 source ,by Williamson⁽¹³⁾; previous work on the ADVANTAGE source calculated by Meigooni et al.⁽¹²⁾; the NAS MED3633 calculated by Li and Palta⁽¹⁵⁾; and the Best ¹⁰³Pd calculated by Meigooni et al.⁽¹⁴⁾

Fig. 2 compares the g(r) for the new source with those for other commercially available sources such as the Model 200 source determined by Williamson,⁽¹³⁾ previous work on the ADVANTAGE source determined by Meigooni et al.,⁽¹²⁾ NAS MED3633 determined by Li and Palta,⁽¹⁵⁾ and the Best ¹⁰³Pd determined by Meigooni et al.⁽¹⁴⁾ The figure shows that the radial dose function of the ADVANTAGE ¹⁰³Pd source is in good agreement with those of the other sources.

Fig. 3 shows the variation of the anisotropy function with radial distance in water. The F(r,θ) of the ADVANTAGE source in water was compared with those of the Model 200 source determined by Weaver,⁽¹⁶⁾ previous work on the ADVANTAGE source determined by Meigooni et al.,⁽¹²⁾ the NAS MED3633 determined by Li and Palta,⁽¹⁵⁾ and the Best ¹⁰³Pd determined by Meigooni et al.⁽¹⁴⁾ (Figs. 4 and 5). The figures show good agreement between the ADVANTAGE source and other ¹⁰³Pd sources for angular ranges of 20 degrees to 90 degrees. Below 20 degrees, differences in endcap construction yield significant deviations in the plotted anisotropy functions.

Table 3 presents the values of the measured and calculated anisotropy functions, anisotropy factors, and anisotropy constants for the ADVANTAGE source in liquid water. Table 4 compares the anisotropy factors and constant of the ADVANTAGE source with other commercially available ¹⁰³Pd sources. The anisotropy constant of the ADVANTAGE ¹⁰³Pd source in water was found to be 0.880 ± 0.040.

The dosimetric characteristics of the ADVANTAGE source were theoretically determined based on TG-43(U1) recommendations. These characteristics were found to be comparable to the values reported for other commercially available ¹⁰³Pd sources. As per TG-43(U1), the parameters determined in liquid water are recommended for clinical applications.

ACKNOWLEDGMENT

This project was supported by IsoAid LLC. Special thanks are due to Ali Meigooni for his assistance in the preparation of this manuscript.

REFERENCES

1. Wallner K, Merrick G, True L, Cavanaugh W, Simpson C, Butler W. ¹²⁵I versus ¹⁰³Pd for low-risk prostate cancer: modality outcomes from a prospective randomized multicenter trial. Cancer J. 2002;8(1):67­73.

2. Dattoli M, Wallner K, True L, Cash J, Sorace R. Long term outcomes after treatment with external beam radiation therapy and ¹⁰³Pd for patients with higher risk prostate carcinoma. Cancer J. 2003;97(4):979­983.

3. Porrazzo MS, Hilaris BS, Moorthy CR, et al. Permanent interstitial implantation using ¹⁰³palladium: The New York Medical College preliminary experience. Int J Radiat Oncol Biol Phys. 1992;23(5):1033­1036.

4. Blasko JC, Wallner K, Grimm PD, Ragde H. Prostate specific antigen based control following ultrasound guided ¹²⁵I implantation for stage T1/T2 prostate carcinoma. J Urol. 1995;154(3):1096­1099.

5. Williamson JF. Monte Carlo evaluation of kerma at a point for photon transport problems. Med Phys. 1987;14(4):567­576.

6. Dillman LT, Van der Lage FC. Radionuclide Decay Schemes and Nuclear Parameters for Use in Radiation-Dose Estimates. NM/MIRD pamphlet No. 10. Revised edition. New York (NY): Society of Nuclear Medicine, Medical Internal Radiation Dose Committee; 1975.

7. Williamson JF. Monte Carlo simulation of photon transport phenomena. In: Morin RL, editor. Monte Carlo Simulation in the Radiological Sciences. Boca Raton (FL): CRC Press; 1988: 53­102.

8. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995;22(2):209­234.

9. Meigooni AS, Williamson JF, Nath R. Single source dosimetry for interstitial brachytherapy. In: Williamson JF, Thomadson BR, Nath R, editors. Brachytherapy Physics. Madison (WI): Medical Physics Publishing Corporation; 1995: 210­233.

10. Rivard MJ, Coursey BM, DeWerd LA, et al. Update of AAPM Task Group No. 43 report: a revised AAPM protocol for brachytherapy does calculations. Med Phys. 2004;31(3):633­674. [Erratum in: Med Phys. 2004;31(12):3532­3533]

11. Williamson JF, Coursey BM, DeWerd LA, Hanson WF, Nath R, Ibbott GS. Dosimetric prerequisites for routine clinical use of new low energy photon interstitial brachytherapy sources. Med Phys. 1998;25(12):2269­2270.

12. Meigooni AS, Dini SA, Dou K, Awan SB, Gopalakrishnan G. Experimental and Monte Carlo dosimetric characterization of ADVANTAGE ¹⁰³Pd. Appl Radiat Isot. 2006;64(8):881­887.

13. Williamson JF. Monte Carlo modeling of the transverse-axis dose distribution of the model 200 ¹⁰³Pd interstitial brachytherapy source. Med Phys. 2000;27(4):643­654.

14. Meigooni AS, Bharucha Z, Yoe­Sein M, Sowards K. Dosimetric characteristics of the Best double-wall ¹⁰³Pd brachytherapy source. Med Phys. 2001;28(12):2568­2575.

15. Li Z, Palta JR, Fan JJ. Monte Carlo calculations and experimental measurements of dosimetry parameters of a new ¹⁰³Pd source. Med Phys. 2000;27(5):1108­1112.

16. Weaver KA. Anisotropy functions for ¹²⁵I and ¹⁰³Pd sources. Med Phys. 1998;25(12):2271­2278.